




ACTIVITY OF NEW ANTIBACTERIAL PRODUCTS ON PRIORITY PATHOGENS


Authors: Claudia Agyeere (@Agyeere9), Gideon Danso (@Gideon_0703), Akeemat Ayinla (@That_Hakeemah), Frederick Allou (@Freddie), Duong Gia Khanh(@Khanh)

This infographic presents a summary of the results of testing new antibacterial products on WHO-classified priority pathogens.



- ✓ The AMR products tested were of two types: the traditionally used antibiotics and non-traditional products.
- ✓ Antibiotics made up the majority (57.2%) of the product type.
- ✓ Out of the 267 antibacterial entries tested, 146 (54.7%) showed activity against priority pathogens.



- ✓ Majority of the products tested were in development phase I.



- ✓ Activity against priority pathogens is highest when drugs are administered via the intravenous route (IV).



- ✓ The antibacterials tested were most active against Critical Priority Pathogens.

